Cardiff Oncology (Cardiff Oncology) Operating Cash Flow per Share : $-0.69 (TTM As of Dec. 2023)

View and export this data going back to 1997. Start your Free Trial

What is Cardiff Oncology Operating Cash Flow per Share?

Cardiff Oncology's operating cash flow per share for the three months ended in Dec. 2023 was $-0.16. Cardiff Oncology's operating cash flow per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.69.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 4.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 32.90% per year. During the past 10 years, the average Operating Cash Flow per Share Growth Rate was 42.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the OCF Growth Rate using Operating Cash Flow per Share data.

The historical rank and industry rank for Cardiff Oncology's Operating Cash Flow per Share or its related term are showing as below:

CRDF' s 3-Year OCF Growth Rate Range Over the Past 10 Years
Min: -49.8 Med: 4 Max: 74.7
Current: 4

During the past 13 years, Cardiff Oncology's highest 3-Year average Operating Cash Flow per Share Growth Rate was 74.70% per year. The lowest was -49.80% per year. And the median was 4.00% per year.

CRDF's 3-Year OCF Growth Rate is ranked better than
50.72% of 1242 companies
in the Biotechnology industry
Industry Median: 3.6 vs CRDF: 4.00

Cardiff Oncology Operating Cash Flow per Share Historical Data

The historical data trend for Cardiff Oncology's Operating Cash Flow per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cardiff Oncology Operating Cash Flow per Share Chart

Cardiff Oncology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Operating Cash Flow per Share

Get a 7-Day Free Trial

-2.22

-0.78

-0.59

-0.78

-0.69

Cardiff Oncology Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Operating Cash Flow per Share	Get a 7-Day Free Trial															-0.21	-0.19	-0.16	-0.18	-0.16

Competitive Comparison of Cardiff Oncology's Operating Cash Flow per Share

For the Biotechnology subindustry, Cardiff Oncology's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cardiff Oncology's Price-to-Operating-Cash-Flow Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cardiff Oncology's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Cardiff Oncology's Price-to-Operating-Cash-Flow falls into.

Cardiff Oncology Operating Cash Flow per Share Calculation

Operating Cash Flow per Share is the amount of Cash Flow from Operations per outstanding share of the company's stock.

Cardiff Oncology's Operating Cash Flow per Share for the fiscal year that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (A: Dec. 2023 )	=	Cash Flow from Operations (A: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (A: Dec. 2023 )
	=	-30.887	/	44.677
	=	-0.69

Cardiff Oncology's Operating Cash Flow per Share for the quarter that ended in Dec. 2023 is calculated as

Operating Cash Flow per Share (Q: Dec. 2023 )	=	Cash Flow from Operations (Q: Dec. 2023 )	/	Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
	=	-7.139	/	44.677
	=	-0.16

Operating Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.69

Cardiff Oncology Operating Cash Flow per Share Related Terms

Thank you for viewing the detailed overview of Cardiff Oncology's Operating Cash Flow per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Cardiff Oncology (Cardiff Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cardiff Oncology Inc (NAS:CRDF) » Definitions » Operating Cash Flow per Share

Comparable Companies

Traded in Other Exchanges

XE7C:Germany

Address

11055 Flintkote Avenue, San Diego, CA, USA, 92121

Website

https://www.cardiffoncology.com

Cardiff Oncology Inc is a clinical-stage, biotechnology company, developing treatment options for cancer patients in indications with the greatest medical need, including KRAS-mutated metastatic colorectal cancer, pancreatic cancer, metastatic castrate-resistant prostate cancer and leukemias.

Executives

Gary W Pace	director	C/O RESMED INC, 14040 DANIELSON STREET, POWAY CA 92064-6857
Fairooz Kabbinavar	officer: Chief Medical Officer	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Mark Erlander	officer: Chief Scientific Officer	C/O TROVAGENE, INC., 11055 FLINTKOTE AVENUE, SUITE A, SAN DIEGO CA 92121
Lale White	director	310 GODDARD, SUITE 150, IRVINE CA 92618
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
James E. Levine	officer: Chief Financial Officer	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Renee P Tannenbaum	director	9220 KIRBY DRIVE, SUITE 500, HOUSTON TX 77054
Tod Smeal	officer: Chief Scientific Officer	11055 FLINTKOTE AVENUE, SA DIEGO CA 92121
Katherine L Ruffner	officer: Chief Medical Officer	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
Mani Mohindru	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Rodney S Markin	director	C/O UNIVERSITY OF NEBR MEDICAL CENTER, 983135 NEBRASKA MEDICAL CENTER, OMAHA NE 68198-3135
Gary S Jacob	director
Vicki Kelemen	officer: Exec. VP and COO	11055 FLINTKOTE AVENUE, SAN DIEGO CA 92121
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Rajeev M. Shah	10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116